KPV

Plain-English version: KPV is a very small protein fragment — just three amino acids long — that scientists copied from the tail end of a natural hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). The whole point of studying this fragment is that it appears to carry most of alpha-MSH's anti-inflammatory power in a simpler, more targeted package.

"KPV" is simply the single-letter code for its three building blocks: K (lysine), P (proline), and V (valine). Alpha-MSH itself is a 13-amino-acid hormone your body produces in the brain, skin, and immune cells, where it helps regulate inflammation, immune activity, and pigment (the tanning response). KPV is the last three amino acids of that hormone, positions 11 through 13.^[6]

Why does that specific tail matter? Because researchers found that this short C-terminal sequence reproduces much of the parent hormone's anti-inflammatory activity without switching on the melanocortin receptors that drive melanin production. In practice, that means KPV can calm inflammation without darkening skin — the feature that separates it from full-length alpha-MSH and from tanning peptides.^[6]

The credibility caveat, stated up front: a promising mechanism in cells and mice is not the same as a proven treatment in people. There are no completed controlled human trials of KPV. Every efficacy and safety finding below comes from mouse models of colitis or from human cell lines grown in a laboratory. KPV is not approved by the FDA for any indication and is not an approved drug, biologic, or supplement; it is sold and handled only as a research chemical labeled "not for human use." For the broader legal picture, see Are Peptides Legal?

Takeaway first: KPV's job is to quiet inflammation from inside the cell. Instead of blocking a surface receptor, it slips into cells and interferes with NF-kB — the master control switch that turns on inflammatory genes. Here is what the verified research actually shows, and where it stops.

1. Getting into the cell (the PepT1 shuttle)

Most peptides cannot easily cross into cells. KPV is unusual: because it is a di/tripeptide, it hitches a ride through a transporter called PepT1, which normally ferries small peptides from digested food into intestinal cells. Work in human intestinal epithelial and immune cells showed KPV is taken up by PepT1 and then, once inside, reduces inflammatory signaling at nanomolar (very low) concentrations.^[2] That PepT1 route is a big part of why KPV is interesting for the gut specifically — inflamed intestinal tissue expresses this transporter.

2. Shutting down NF-kB (the master inflammation switch)

NF-kB is a transcription factor — a protein that switches genes on. When it is activated, it drives production of pro-inflammatory messengers like TNF-alpha, IL-6, and IL-8. In human intestinal cells, KPV lowered IkB-alpha phosphorylation and degradation (the step that normally frees NF-kB to act) and reduced TNF-alpha-driven IL-8 at the mRNA level.^[2] Evidence level: human cell culture.

3. Blocking NF-kB at the nuclear door (the p65 mechanism)

A second study, in human bronchial (airway) epithelial cells, pinned down a more precise mechanism: KPV travels toward the nucleus and competitively blocks the interaction between the NF-kB subunit p65 (RelA) and importin-alpha3, the shuttle protein that carries p65 into the nucleus. No shuttle, no nuclear entry — so p65 never reaches the DNA to switch on inflammatory genes. Importantly, this happens without needing a melanocortin receptor, which is why KPV can act as an anti-inflammatory in tissues that lack those receptors.^[3] Evidence level: human cell culture.

4. Receptor-independent, and not broadly immunosuppressive

A revealing finding from the colitis research: KPV still worked in mice engineered to lack the melanocortin-1 receptor (MC1R), and it even rescued those MC1R-deficient mice from otherwise-fatal colitis — evidence that KPV's anti-inflammatory effect does not depend on that receptor.^[1] Reviews of alpha-MSH and its tripeptides describe this family as immunomodulatory rather than broadly immunosuppressive: they dial down excessive inflammation (in part through IL-10-dependent effects) rather than flattening the whole immune system the way a corticosteroid does.^[6][7]

What we do NOT know

There is no established human pharmacokinetics for KPV — how it is absorbed, distributed, and cleared in people is uncharacterized. There is no human dose-response data. The mechanisms above are real published findings, but they come from human cell lines and mouse models, and mechanism in a dish does not guarantee benefit in a patient.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Nearly every result below is from mice or human cell cultures. That does not make it worthless — it makes it preliminary. Anecdotal human reports exist but are not controlled evidence.

Gut inflammation (the strongest area)

Claim: may calm inflammation in the intestine. Mechanism: PepT1-mediated uptake into intestinal cells followed by NF-kB inhibition. Population: two mouse models of inflammatory bowel disease — DSS-induced colitis and CD45RB-transfer colitis — plus human intestinal cell lines. Effect: KPV produced earlier recovery, significantly stronger body-weight regain, reduced inflammatory infiltrate, and lower colonic myeloperoxidase activity (a marker of neutrophil-driven inflammation); it also rescued MC1R-deficient mice from death.^[1] Separately, in human intestinal and immune cells, KPV cut TNF-alpha-driven IL-8 production.^[2] Limitation: mouse models and human cells only — no IBD patients have been studied in a controlled trial. This gut-inflammation angle is exactly why KPV is often discussed alongside BPC-157 for inflammation goals.

Oral delivery and mucosal healing

Claim: may be delivered by mouth to reach an inflamed gut. Mechanism: nanoparticle packaging protects KPV through the stomach and targets it to inflamed intestinal tissue. Population: a mouse model of ulcerative colitis. Effect: hyaluronic-acid-functionalized nanoparticles loaded with KPV (HA-KPV-NPs), given orally, accelerated mucosal healing and reduced inflammation compared with controls.^[4] Limitation: this used an engineered nanoparticle carrier in mice — it is not evidence that swallowing plain KPV powder reaches the gut intact, and it is not a human result. Free (unprotected) KPV is largely degraded in the digestive tract.

Skin and immune inflammation

Claim: may reduce inflammatory skin reactions. Mechanism: the same NF-kB and IL-10-linked anti-inflammatory activity as the parent hormone, without pigment stimulation. Population: in-vitro and animal models reviewed in the alpha-MSH literature; contact-dermatitis (allergic skin reaction) models. Effect: alpha-MSH and its C-terminal tripeptide suppressed contact-dermatitis sensitization and elicitation, with IL-10-dependent effects.^[6][7] The closest thing to a human signal is indirect: a preliminary report that a topical alpha-MSH cream (the parent hormone, not KPV) reduced nickel-induced contact eczema in people — encouraging context, but not a KPV trial.^[6] Limitation: the direct evidence is preclinical, and the human hint used the parent hormone, not KPV.

Antimicrobial activity

Claim: may directly inhibit certain microbes. Mechanism: effect linked to increased cellular cAMP. Population: in-vitro antimicrobial assays. Effect: alpha-MSH and its C-terminal tripeptide KPV inhibited Staphylococcus aureus colony formation and reduced Candida albicans viability and germ-tube formation across a broad concentration range, down to picomolar levels.^[5] Limitation: test-tube only, and no discrete minimum-inhibitory-concentration (MIC) values for KPV on its own were reported. This dual anti-inflammatory-plus-antimicrobial profile is part of what makes KPV interesting for the gut, where microbial imbalance often accompanies inflammation — but it remains an in-vitro finding.

The honest bottom line on "benefits"

• No human clinical trials have been completed. Human pharmacokinetics, effective doses, and long-term outcomes are unknown.
• The evidence base is narrow. It centers on a handful of colitis models and cell-line experiments, largely from a small number of research groups.
• Publication bias means positive preclinical results are more likely to be published than null ones.
• Anecdotes are not data. Enthusiastic user reports cannot substitute for controlled trials.

Read this first: there is no clinically validated human dose for KPV, because no human dosing trials have been completed. The figures circulating online (and in the table below) are research-supplier convention and anecdote, not numbers drawn from any published human trial. The actual published protocols are in mice and in cell culture, where doses are given per kilogram of body weight or as a concentration in a dish — not as a fixed microgram dose for a person. We describe the commonly cited human figures here for completeness and harm reduction, not as medical guidance.

Commonly cited research protocols (convention, not trial-derived)

Route	Commonly cited dose	Frequency	Typical target	Note
Subcutaneous	200-500 mcg	Once daily	Systemic anti-inflammatory	Abdominal fat pad
Oral (capsule)	200-500 mcg	1-2x daily	Gut inflammation	Free KPV is largely degraded; nanoparticle delivery is what the research used
Topical	Applied to the area	1-2x daily	Skin inflammation	After cleaning the area

Route logic in plain terms: for gut targets, oral makes direct contact with the digestive lining — but remember the mouse gut data used an engineered nanoparticle carrier, not plain powder. For a more systemic anti-inflammatory effect, subcutaneous injection into the abdominal fat pad is the convention. Topical is used for localized skin inflammation.

Reconstitution math, with a worked example

Injectable KPV ships as a lyophilized (freeze-dried) powder, usually in 2 mg or 5 mg vials, that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mcg/mL) = vial amount (mcg) ÷ water added (mL)

Worked example: take a 5 mg vial (that is 5,000 mcg) and add 2 mL of bacteriostatic water. That gives 5,000 ÷ 2 = 2,500 mcg/mL. To draw a 250 mcg dose: 250 ÷ 2,500 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe. A 500 mcg dose is 0.20 mL, or 20 units.

Vial	BAC water	Concentration	250 mcg	500 mcg
5 mg	2 mL	2,500 mcg/mL	0.10 mL (10 units)	0.20 mL (20 units)
2 mg	2 mL	1,000 mcg/mL	0.25 mL (25 units)	0.50 mL (50 units)
2 mg	1 mL	2,000 mcg/mL	0.125 mL (12.5 units)	0.25 mL (25 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until fully dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a step-by-step walkthrough.

Cycle length, timing, and storage

• Cycle: anecdotal protocols run roughly 4-8 weeks, with some gut-focused users extending longer. These durations are convention, not human-trial results.
• Timing: KPV has no strict meal timing for injection. Oral is usually taken on an empty stomach to limit degradation, though as noted, unprotected oral KPV is poorly absorbed.
• Storage: keep lyophilized vials frozen for long-term storage or refrigerated (2-8°C) short-term; refrigerate reconstituted solution and use it within a few weeks; avoid freeze-thaw cycles; protect from light and heat. See the peptide storage guide.

None of the above should be read as a recommendation to self-administer an unapproved compound. It is a description of how the research and community doses are structured.

Straight talk: no serious adverse events have been reported in the published preclinical KPV literature, and reviews describe the alpha-MSH tripeptide family as modulating inflammation rather than broadly suppressing immunity.^[6][7] But there are no human safety data at all — every safety observation is from mice or cell culture. So this is reassurance, not proof. A recurring, under-appreciated risk is product quality: unregulated research vials vary widely, and impurities can cause effects that get blamed on the peptide itself.

Reported and plausible effects

Effect	Frequency	Severity	Notes
Injection-site redness/irritation	Common (anecdotal)	Mild	Transient; typical of any subcutaneous injection
Mild GI upset (oral)	Occasional (anecdotal)	Mild	Reported minimal in studies

Notably, and unlike full-length alpha-MSH or melanocortin agonists such as Melanotan II, KPV does not activate the pigment-producing receptors, so it is not expected to cause skin darkening.^[6] No organ toxicity has been reported in the published preclinical work — but absence of reports in a small animal literature is very different from a demonstrated safety record in humans.

Theoretical risks and who should avoid it

• Active infection: KPV's anti-inflammatory action could in theory blunt an inflammatory response that is needed to clear a pathogen. Unstudied — a reason for caution.
• People on immunosuppressive medication: combining an immune modulator with immunosuppressants has an uncharacterized interaction risk.
• Pregnancy and breastfeeding: no reproductive-safety data exist — avoid.
• Known hypersensitivity to alpha-MSH-derived peptides.

The limitations you must keep in mind

• All safety data are from mice and cell cultures, from a limited number of research groups.
• No completed human trials means human pharmacokinetics, drug interactions, and long-term safety are unknown.
• Any human reports are uncontrolled and prone to bias.
• Contaminants from low-quality product are a real and separate hazard.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: KPV is an unregulated research compound, so purity and identity vary enormously between suppliers. For an unproven peptide, contamination is arguably a bigger practical risk than the peptide itself. Knowing how to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the lysine-proline-valine sequence (~342 Da for the free tripeptide).
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed liquid "ready to use" peptide (shorter shelf life, contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any indication. KPV is not an approved drug, biologic, or dietary supplement.
• Research-use only: it is sold and shipped labeled "not for human use." There is no approved human therapeutic containing KPV; all evidence is preclinical.
• Compounding — July 2026 recommendation: KPV is not on the FDA's 503A compounding list, but on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding it, over the objection of FDA staff who found no human trials. The vote is non-binding and does not make KPV legal to compound; FDA rulemaking would still be required, and that process has historically taken years rather than months. See our July 2026 FDA peptide panel vote report.
• Not a controlled substance: KPV is not DEA-scheduled.

For the complete legal picture, read Are Peptides Legal?

KPV is usually weighed against a few neighbors. None of these comparisons are backed by head-to-head human trials — they contrast proposed mechanisms and the preclinical literature.

Peptide	Primary emphasis	Routes	Key difference
KPV	NF-kB inhibition / gut inflammation	SC, oral, topical	Targeted anti-inflammatory, no pigmentation effect
BPC-157	Tissue repair / gut-lining healing	SC, oral	Broader tissue regeneration and angiogenesis
Melanotan II	Melanocortin receptor agonist	SC	Stimulates pigment (tanning); a very different goal

The most common pairing is KPV with BPC-157 for gut goals: they target complementary jobs, with KPV lowering the inflammatory signal via NF-kB while BPC-157 is studied for repairing and protecting the tissue itself. Both remain preclinical for these uses.